S Squared Technology Continues to Hold Position in Inphi (IPHI); Neurocrine Biosciences (NBIX) Share Value Rose While Emory University Has Decreased Its Position

April 25, 2018 - By Marguerite Chambers

Inphi Corporation (NYSE:IPHI) Logo

S Squared Technology Llc increased its stake in Inphi Corp (IPHI) by 19.6% based on its latest 2017Q4 regulatory filing with the SEC. S Squared Technology Llc bought 30,100 shares as the company’s stock declined 21.51% with the market. The hedge fund held 183,676 shares of the semiconductors company at the end of 2017Q4, valued at $6.72 million, up from 153,576 at the end of the previous reported quarter. S Squared Technology Llc who had been investing in Inphi Corp for a number of months, seems to be bullish on the $1.36 billion market cap company. The stock increased 3.49% or $1.06 during the last trading session, reaching $31.42. About 1.89 million shares traded or 72.89% up from the average. Inphi Corporation (NYSE:IPHI) has declined 35.04% since April 25, 2017 and is downtrending. It has underperformed by 46.59% the S&P500.

Emory University decreased its stake in Neurocrine Biosciences Inc (NBIX) by 18.16% based on its latest 2017Q4 regulatory filing with the SEC. Emory University sold 5,537 shares as the company’s stock rose 13.16% while stock markets declined. The institutional investor held 24,945 shares of the health care company at the end of 2017Q4, valued at $1.94 million, down from 30,482 at the end of the previous reported quarter. Emory University who had been investing in Neurocrine Biosciences Inc for a number of months, seems to be less bullish one the $7.05B market cap company. The stock decreased 3.60% or $2.93 during the last trading session, reaching $78.43. About 636,439 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 91.92% since April 25, 2017 and is uptrending. It has outperformed by 80.37% the S&P500.

Since January 3, 2018, it had 1 insider buy, and 6 sales for $2.85 million activity. Ogawa Richard sold $125,757 worth of stock. $2.74M worth of stock was sold by EDMUNDS JOHN on Wednesday, February 14. 179 shares valued at $6,786 were sold by Torten Ron on Wednesday, January 3.

Investors sentiment increased to 1.15 in Q4 2017. Its up 0.30, from 0.85 in 2017Q3. It is positive, as 18 investors sold IPHI shares while 53 reduced holdings. 25 funds opened positions while 57 raised stakes. 50.71 million shares or 4.56% more from 48.49 million shares in 2017Q3 were reported. 1.10 million are held by State Street. Quentec Asset Management Limited Liability Company invested in 3.54% or 613,663 shares. Rhumbline Advisers accumulated 42,617 shares or 0% of the stock. Pnc Financial Service Group has 909 shares for 0% of their portfolio. Congress Asset Mngmt Ma holds 0.01% of its portfolio in Inphi Corporation (NYSE:IPHI) for 16,189 shares. Tygh owns 118,719 shares. Gagnon Ltd Company has 10,383 shares. Adage Cap Partners Lc stated it has 657,000 shares. Alliancebernstein LP holds 0.01% or 222,300 shares. Barclays Pcl reported 0% stake. Dimensional Fund Advsrs Lp owns 207,677 shares or 0% of their US portfolio. Emerald Advisers Pa reported 313,551 shares. Deutsche Bank & Trust Ag reported 777,299 shares or 0.02% of all its holdings. Gilder Gagnon Howe Com Ltd Liability Com invested in 0.1% or 202,293 shares. Legal And General Gru Plc invested 0% of its portfolio in Inphi Corporation (NYSE:IPHI).

Among 18 analysts covering Inphi (NYSE:IPHI), 13 have Buy rating, 2 Sell and 3 Hold. Therefore 72% are positive. Inphi had 82 analyst reports since July 29, 2015 according to SRatingsIntel. Jefferies maintained the shares of IPHI in report on Tuesday, August 9 with “Buy” rating. The company was maintained on Tuesday, February 6 by Cowen & Co. The stock of Inphi Corporation (NYSE:IPHI) has “Strong Buy” rating given on Monday, February 8 by Needham. As per Wednesday, October 28, the company rating was maintained by Northland Capital. The firm earned “Buy” rating on Monday, October 12 by Stifel Nicolaus. The stock of Inphi Corporation (NYSE:IPHI) has “Buy” rating given on Wednesday, November 1 by Cowen & Co. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, February 8. The firm earned “Strong Buy” rating on Wednesday, October 28 by Needham. The firm has “Buy” rating given on Monday, December 18 by Stifel Nicolaus. The rating was maintained by Jefferies on Tuesday, July 4 with “Buy”.

Since January 2, 2018, it had 0 insider purchases, and 22 sales for $29.59 million activity. Shares for $227,494 were sold by Lippoldt Darin on Monday, February 5. 2,046 shares were sold by Gano Kyle, worth $169,914. Lloyd-Smith Malcolm sold $79,863 worth of stock or 960 shares. $128,575 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by Bozigian Haig P.. 5,000 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares with value of $423,341 were sold by LYONS GARY A. OBrien Christopher Flint sold $217,341 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Monday, February 5.

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.35, from 1.66 in 2017Q3. It fall, as 18 investors sold NBIX shares while 76 reduced holdings. 58 funds opened positions while 65 raised stakes. 91.25 million shares or 1.56% less from 92.69 million shares in 2017Q3 were reported. State Board Of Administration Of Florida Retirement owns 0.02% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 116,057 shares. Cap Ww accumulated 0.01% or 688,000 shares. Us Commercial Bank De stated it has 398 shares or 0% of all its holdings. Parametric Associate Lc holds 0.01% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 74,530 shares. California Public Employees Retirement Systems owns 192,135 shares. Rockefeller Fincl reported 0% stake. Vident Investment Advisory Limited Co holds 0.01% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 2,674 shares. Deutsche Retail Bank Ag has 968,205 shares. Sg Americas Secs Lc accumulated 0% or 4,428 shares. First Personal Ser, a North Carolina-based fund reported 758 shares. Public Employees Retirement Association Of Colorado reported 178,399 shares. 3,005 were accumulated by Trexquant Investment Limited Partnership. Shanda Asset Mgmt Ltd has invested 0.12% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Moreover, First Advsr Ltd Partnership has 0.16% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 852,835 shares. Neuberger Berman Grp Incorporated Ltd Liability Co has 476,795 shares for 0.04% of their portfolio.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on May, 8. They expect $-0.32 earnings per share, up 64.44% or $0.58 from last year’s $-0.9 per share. After $0.07 actual earnings per share reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -557.14% negative EPS growth.

Emory University, which manages about $116.54M US Long portfolio, upped its stake in Acadia Pharmaceuticals Inc (NASDAQ:ACAD) by 14,781 shares to 67,758 shares, valued at $2.04 million in 2017Q4, according to the filing. It also increased its holding in Tesaro Inc (NASDAQ:TSRO) by 5,878 shares in the quarter, for a total of 20,407 shares, and has risen its stake in Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 54 analyst reports since August 18, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, November 2 by H.C. Wainwright. The rating was maintained by Cowen & Co with “Buy” on Monday, September 25. The stock has “Buy” rating by Oppenheimer on Thursday, September 7. On Thursday, November 2 the stock rating was maintained by Barclays Capital with “Overweight”. The rating was maintained by Cowen & Co with “Buy” on Friday, August 4. The firm earned “Buy” rating on Wednesday, February 14 by H.C. Wainwright. As per Wednesday, June 29, the company rating was initiated by H.C. Wainwright. The rating was maintained by Needham with “Buy” on Thursday, February 22. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, October 25 report. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Thursday, November 2 by Deutsche Bank.

Inphi Corporation (NYSE:IPHI) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>